Hypogonadism Clinical Trial
Official title:
A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males
This will be a phase 1/2a, open-label, single-center study with 3 periods. The aims of the
study are to:
1. evaluate the dose-response curve following ascending single doses of TSX-011;
2. confirm optimum dosing conditions;
3. evaluate the efficacy of single or multiple daily adaptive dosing; and
4. evaluate the safety and tolerability of TSX-011.
This will be a phase 1/2a, open-label, single-center study with 3 periods. The aims of the
study are to: 1) evaluate the dose-response curve following ascending single doses of
TSX-011; 2) confirm optimum dosing conditions; 3) evaluate the efficacy of single or multiple
daily adaptive dosing; and 4) evaluate the safety and tolerability of TSX-011. Up to 24
hypogonadal men will be enrolled in this study to yield 16 evaluable subjects, and it is
desired that the same 24 subjects participate in all 3 study periods.
Period 1 is an ascending single-dose study of TSX-011 at 3 doses, with the lowest dose
administered under fed and fasted conditions: 190 mg TSX-011 in the fed state, 190 mg TSX-011
in the fasted state, 380 mg TSX-011 in the fed state, and 570 mg TSX-011 in the fed state.
Before exposure to TSX-011, a 24 hour baseline measurement of testosterone and DHT will be
performed for each subject. Samples for analysis of testosterone will be obtained at the
following time points on Day -1: hour 0 (8 am ± 60 minutes) and 1.5, 3, 4.5, 6, 8, 12, 16,
and 24 hours (± 15 minutes for each time point).
The day following the sampling for endogenous testosterone (Day 1) in Period 1, each subject
will receive the first single dose of TSX-011 (190 mg) under fed conditions. Following
administration of TSX-011, blood samples will be obtained over a 24-hour period for PK
analysis. Subjects will undergo a minimum 3-day and up to 7-day washout period between each
of the doses of TSX-011 in Period 1. After the 570 mg TSX 011 dose in Period 1, a minimum
3-day and up to 7-day washout period will occur before the start of Period 2.
Period 2 is a twice-daily dosing period, where fed subjects will be dosed with 380 mg TSX-011
twice daily for 15 days (Days 1 through 15). Pharmacokinetic assessments over 24 hours will
occur on Days 1 and 15. The TSX-011 dose will be titrated up or down beginning with the Day
16 (Period 3) morning dose, based on established dosing rules.
Period 3 is a dose-adjusted adaptive design period that begins on Day 16, with the first
adjusted TSX-011 dose administered in the fed state on a once-daily or twice-daily schedule.
The 6-hour postdose (± 15 minutes) testosterone level on Day 19 will be used to perform the
second and final TSX-011 dose adjustment, based on established criteria. As specified by the
dose adjustment rules, Day 26 begins with either a once-daily, twice-daily, or thrice-daily
fed dose schedule. The thrice-daily dose schedule will be administered only to
non-responders. On Day 30, a 24 hour PK assessment will be performed, and the subject's
participation in the study is completed the morning of Day 31.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03126656 -
Effects of Testosterone on Myocardial Repolarization
|
Phase 4 | |
Terminated |
NCT02419105 -
Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors
|
Phase 3 | |
Withdrawn |
NCT02137265 -
Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism
|
N/A | |
Completed |
NCT02222558 -
Oral Testosterone for the Treatment of Hypogonadism in Males
|
Phase 2 | |
Completed |
NCT02233751 -
Pharmacokinetic Study of Subcutaneous Testosterone Enanthate
|
Phase 1 | |
Completed |
NCT01887418 -
Pharmacokinetic Study of Testosterone Enanthate
|
Phase 1/Phase 2 | |
Terminated |
NCT01092858 -
NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)
|
Phase 4 | |
Completed |
NCT00624624 -
Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism
|
N/A | |
Completed |
NCT00752869 -
Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement
|
Phase 4 | |
Completed |
NCT00613288 -
Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism
|
N/A | |
Completed |
NCT00838838 -
Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis
|
N/A | |
Completed |
NCT00119483 -
Older Men and Testosterone
|
N/A | |
Completed |
NCT00004438 -
Leuprolide in Treating Adults With Hypogonadotropism
|
N/A | |
Withdrawn |
NCT00398034 -
Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study.
|
Phase 2 | |
Completed |
NCT02937740 -
Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natestoâ„¢
|
Phase 4 | |
Completed |
NCT02921386 -
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
|
Phase 2 | |
Completed |
NCT01717768 -
Oral Testosterone for the Treatment of Hypogonadism
|
Phase 2 | |
Terminated |
NCT01460654 -
Testosterone and Alendronate in Hypogonadal Men
|
Phase 2 | |
Completed |
NCT00998933 -
Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure
|
Phase 1 | |
Completed |
NCT00663793 -
ORAL T-6: Oral Androgens in Man-6
|
Phase 1 |